Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Oncoinvent ASA's Enterprise Value is kr66.55 Mil.
Oncoinvent ASA's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was kr-136.08 Mil. Therefore, Oncoinvent ASA's EV-to-EBIT ratio for today is -0.49.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Oncoinvent ASA's Enterprise Value is kr66.55 Mil.
Oncoinvent ASA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was kr-132.36 Mil. Therefore, Oncoinvent ASA's EV-to-EBITDA ratio for today is -0.50.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Oncoinvent ASA's Enterprise Value is kr66.55 Mil.
Oncoinvent ASA's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was kr16.07 Mil. Therefore, Oncoinvent ASA's EV-to-Revenue ratio for today is 4.14.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Oncoinvent ASA's Enterprise Value is kr66.55 Mil.
Oncoinvent ASA's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was kr-138.47 Mil. Therefore, Oncoinvent ASA's EV-to-FCF ratio for today is -0.48.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Oncoinvent ASA (CHIX:ONCINo) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Oncoinvent ASA's current Enterprise Value is kr66.55 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Oncoinvent ASA's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was kr-136.08 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Oncoinvent ASA's current Enterprise Value is kr66.55 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Oncoinvent ASA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was kr-132.36 Mil.
Oncoinvent ASA's current Enterprise Value is kr66.55 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Oncoinvent ASA's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was kr16.07 Mil.
Oncoinvent ASA's current Enterprise Value is kr66.55 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Oncoinvent ASA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was kr-138.47 Mil.
Oncoinvent ASA's current Enterprise Value is kr66.55 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Oncoinvent ASA's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was kr-138.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncoinvent ASA Enterprise Value Related Terms
Oncoinvent ASA Enterprise Value Historical Data
* Premium members only.
The historical data trend for Oncoinvent ASA's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ONCINO vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Oncoinvent ASA's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncoinvent ASA Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Oncoinvent ASA's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Oncoinvent ASA's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncoinvent ASA (CHIX:ONCINO) has a Enterprise Value of kr66.55 Mil as of Jul. 03, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Oncoinvent ASA and its competitors.
Is Oncoinvent ASA's Enterprise Value too high?
Oncoinvent ASA's current Enterprise Value is kr66.55 Mil. Overall, Oncoinvent ASA has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's Enterprise Value compare to VRTX and REGN?
Oncoinvent ASA's Enterprise Value of kr66.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Oncoinvent ASA and its competitors. Oncoinvent ASA's current Enterprise Value is kr66.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (CHIX:ONCINO) has a current Enterprise Value of kr66.55 Mil. The stock's GF Value™ is kr20,159.96, compared to a current price of kr1,039.91 — trading 94.8% below its estimated fair value. The current Enterprise Value is kr66.55 Mil. Oncoinvent ASA's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Oncoinvent ASA (CHIX:ONCINO), the current Enterprise Value is kr66.55 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncoinvent ASA (CHIX:ONCINO) Overvalued in 2026?
Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued.
The current stock price of kr1,039.91 is trading 94.8% below its estimated GF Value™ of kr20,159.96.
Key valuation signals for CHIX:ONCINO:
Enterprise Value: kr66.55 Mil
GF Value™: kr20,159.96 vs. price of kr1,039.91 (94.8% below fair value)
No single metric tells the full story. See the CHIX:ONCINO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score
Get the complete analysis for CHIX:ONCINO
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ONCINO has been successfully added to your 
